@article{Akter_Islam_Morshed_Ara_Rahman_Ahmmed_Yeamin_2022, title={Efficacy and Safety of Piperacillin-Tazobactam and Cefepime as Empirical Therapy for Febrile Neutropenic Children with Acute Lymphoblastic Leukaemia (ALL)}, volume={45}, url={https://banglajol.info/index.php/BJCH/article/view/60079}, DOI={10.3329/bjch.v45i2.60079}, abstractNote={<p><strong>Background: </strong>Infection is a major clinical challenge in ALL treatment. Prompt administration of empirical antibiotic in febrile neutropenic patients has reduced the mortality. Both Cefepime or Piperacillin-Tazobactam has been used as empirical treatment.</p> <p><strong>Objective: </strong>To compare the efficacy and safety between Piperacillin-Tazobactam with Cefepime in febrile neutropenic children with ALL.</p> <p><strong>Materials and methods: </strong>This randomized study was conducted from August 2015 to August 2016 in BSMMU. Sixty one episodes of febrile neutropenia in children with ALL, aged 0 to18 years were included in this study. Patients were randomized into two groups. One group received Piperacilln/Tazobactam and another group received Cefepime and data of 60 febrile neutropenic episodes were analyzed.</p> <p><strong>Results: </strong>Febrile neutropenic episodes in the Piperacillin/Tazobactam group were 28 and in Cefepime group was 32 episodes and 34(57.63%) were male and 25 (42.37%) female. Median age was 5 years and 38(62.3%) neutropenic episodes were in induction phase. Majority had fever without focus 21(35%). Microorganisms isolated in 13 (21.66%) patients and majority 6 (46.15%) had blood infection. Most of the isolated organisms were Gram negative 11(84.61%). Overall treatment success without modification in the Piperacillin/Tazobactam group was 17(60.7%) and in Cefepime group 18 (56.3%) and that comparison was not statistically significant (p= 0.732). Significant difference was also not found comparing the mean duration of fever, neutropenia and hospital stay.</p> <p><strong>Conclusion: </strong>Both Piperacillin/Tazobactam and Cefepime were found effective and safe as an empirical therapy for febrile neutropenic children with ALL.</p> <p>BANGLADESH J CHILD HEALTH 2021; VOL 45 (2) : 83-88</p>}, number={2}, journal={Bangladesh Journal of Child Health}, author={Akter, Mehnaz and Islam, Afiqul and Morshed, Akm Amirul and Ara, Zannat and Rahman, SM Rezanur and Ahmmed, Md Tanvir and Yeamin, Md Bani}, year={2022}, month={Jun.}, pages={83–88} }